drugset / Trial / NCT04683029

A Study of Guselkumab in Participants With Systemic Sclerosis

NCT04683029

Phase 2 Completed 56 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).

Timeline

Start
2021-02-24
Primary completion
2023-05-17
Completion
2024-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody Intravenous

Indications